Pete Najarian Moderna MRNA-Q BUY May 13, 2022

A staple, and that sector is starting to outperform the market. A value play. His target is around $200-ish, if it can break resistance around $140. If it fails, give it a few days, and then walk away if you have to.

It's had a huge price surge recently and is now too pricey. Prefers Pfizer.

Moderna rallied 29% in May after a good report and news on developing a bird flu vaccine to fight that epidemic. Another boost came when the government approved their RSV vaccine. But Moderna is expected to lose money in the foreseeable future. Instead, look at biopharma.

They aren't producing the personalized cancer vaccines he expected, nor using AI as he hoped.

Down 33% the past month and could fall more. It isn't making any money and isn't delivering cancer vaccines.

They should have done something with the money they had, and are now losing money hand over fist.

They aren't delivering on the things--vaccine results--they promise. He struggles with this stock.

Post-Covid, they have a pipeline of drugs under development, related to vaccines and cancer. This is higher-risk in health care. They have $3 billion in revenues, but are spending a lot in R&D, more than their revenues, so they're not profitable. 

No revenue growth and the company seems unconcerned that they are losing so much money. This is why sentiment has turned against MRNA.

Chart over 5 years shows how it went parabolic, and then gave it all back. Question is whether there are adjacent markets where it can use its technology, and the answer is too difficult to handicap. Biotech tends to be a binary business, boom or bust. He's not an expert in biotech, so is not comfortable participating.